X4 Pharmaceuticals Inc (NASDAQ: XFOR)’s stock price has dropped by -3.65 in relation to previous closing price of 0.61. Nevertheless, the company has seen a loss of -7.64% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-10 that X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Dan Ferry – IR Paula Ragan – CEO Adam Mostafa – CFO Mark Baldry – CCO Conference Call Participants David Bautz – Zacks Small-Cap Research Stephen Willey – Stifel Leah Cann – Brookline Capital Markets RK – H.C. Wainwright Ed Tenthoff – Piper Sandler Kristen Kluska – Cantor Operator Good morning, everyone, and welcome to X4 Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Is It Worth Investing in X4 Pharmaceuticals Inc (NASDAQ: XFOR) Right Now?
X4 Pharmaceuticals Inc (NASDAQ: XFOR) has a higher price-to-earnings ratio of 6.81x compared to its average ratio, The 36-month beta value for XFOR is at 0.40. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for XFOR is 117.76M, and currently, shorts hold a 12.50% of that float. The average trading volume for XFOR on August 14, 2024 was 2.07M shares.
XFOR’s Market Performance
The stock of X4 Pharmaceuticals Inc (XFOR) has seen a -7.64% decrease in the past week, with a -23.23% drop in the past month, and a -40.85% fall in the past quarter. The volatility ratio for the week is 7.94%, and the volatility levels for the past 30 days are at 8.15% for XFOR. The simple moving average for the past 20 days is -21.23% for XFOR’s stock, with a -35.91% simple moving average for the past 200 days.
Analysts’ Opinion of XFOR
Many brokerage firms have already submitted their reports for XFOR stocks, with B. Riley Securities repeating the rating for XFOR by listing it as a “Neutral.” The predicted price for XFOR in the upcoming period, according to B. Riley Securities is $1 based on the research report published on December 12, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see XFOR reach a price target of $3. The rating they have provided for XFOR stocks is “Buy” according to the report published on August 30th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to XFOR, setting the target price at $3 in the report published on December 22nd of the previous year.
XFOR Trading at -27.71% from the 50-Day Moving Average
After a stumble in the market that brought XFOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.57% of loss for the given period.
Volatility was left at 8.15%, however, over the last 30 days, the volatility rate increased by 7.94%, as shares sank -21.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.62% lower at present.
During the last 5 trading sessions, XFOR fell by -7.49%, which changed the moving average for the period of 200-days by -23.08% in comparison to the 20-day moving average, which settled at $0.7321. In addition, X4 Pharmaceuticals Inc saw -30.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XFOR starting from Taveras Arthur, who sale 14,235 shares at the price of $0.88 back on Mar 11 ’24. After this action, Taveras Arthur now owns 234,301 shares of X4 Pharmaceuticals Inc, valued at $12,552 using the latest closing price.
Ragan Paula, the President and CEO of X4 Pharmaceuticals Inc, sale 49,678 shares at $0.88 during a trade that took place back on Mar 11 ’24, which means that Ragan Paula is holding 765,068 shares at $43,856 based on the most recent closing price.
Stock Fundamentals for XFOR
Current profitability levels for the company are sitting at:
- -219.54 for the present operating margin
- -0.93 for the gross margin
The net margin for X4 Pharmaceuticals Inc stands at 31.32. The total capital return value is set at -0.68. Equity return is now at value 21.77, with 9.18 for asset returns.
Based on X4 Pharmaceuticals Inc (XFOR), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -1.48. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is -38.41.
Currently, EBITDA for the company is -105.53 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 51.92. The receivables turnover for the company is 0.66for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.07.
Conclusion
In conclusion, X4 Pharmaceuticals Inc (XFOR) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
